Supernus Announces Distribution of Common Stock by NEA
November 12 2015 - 3:20PM
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty
pharmaceutical company focused on developing and commercializing
products for the treatment of central nervous system diseases,
today announced that it has received notice that, effective
following the close of trading on November 11, 2015, New Enterprise
Associates (NEA) distributed an aggregate of 3,820,625 shares of
Supernus Pharmaceuticals common stock to its partners. "The
distribution announced today is a continuation of the actions NEA
took in June 2015 to distribute a portion of its position to its
limited partners after holding that position for over nine years,"
stated Jack Khattar, president and chief executive officer of
Supernus. The NEA funds continue to hold 3,820,625 shares.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical
company focused on developing and commercializing products for the
treatment of central nervous system diseases. The Company has two
marketed products for epilepsy, Oxtellar XR® (extended-release
oxcarbazepine) and Trokendi XR® (extended-release topiramate). The
Company is also developing several product candidates to address
large market opportunities in psychiatry, including SPN-810 for the
treatment of impulsive aggression in patients with ADHD in
conjunction with standard ADHD treatment, and SPN-812 for ADHD.
CONTACT: Jack A. Khattar, President and CEO
Gregory S. Patrick, Vice President and CFO
Supernus Pharmaceuticals, Inc.
Tel: (301) 838-2591
Or
Investor Contact:
Peter Vozzo
Westwicke Partners
Office: (443) 213-0505
Mobile: (443) 377-4767
Email: peter.vozzo@westwicke.com
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Apr 2023 to Apr 2024